Drug intelligence / Profile preview

BR3006-2

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR3006-2 is an investigational small molecule drug developed by Boryung Corp. It has been studied in Phase 1 clinical trials primarily to evaluate its pharmacokinetics, safety, and potential drug-drug interactions when administered alone or in combination with related compounds (BR3006-1 and BR3006-3) in healthy volunteers. The primary therapeutic area of interest for the broader "BR-3006" program is endocrinology and metabolic diseases, specifically type 2 diabetes mellitus. However, the precise mechanism of action and molecular target(s) for BR3006-2 have not been publicly disclosed as of June 2025[3][7]. All available studies to date have focused on early-stage safety and interaction assessments rather than efficacy.

Other names: BR3006-2BR-3006-2BR 3006-2

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on BR3006-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR3006-2.

Explore the full profile